. Author manuscript; available in PMC: 2018 May 28.

Published in final edited form as: Blood Cells Mol Dis. 2016 Nov 9;62:32–37. doi: 10.1016/j.bcmd.2016.11.002

Table 2.

Analysis of association between SNPs and HbF levels at baseline, MTD, and with delta HbF following HU treatment.

Gene	SNP	Genotype	MAF	Baseline HbF		MTD HbF		Delta HbF
Gene	SNP	Genotype	MAF	β	P-value	β	P-value	β	P-value
BCL11A	rs1427407	G>T	0.273	1.84	0.033	3.30	0.004	2.55	0.021
	rs4671393	G>A	0.282	2.09	0.006	3.16	0.009	2.02	0.069
	rs11886868	T>C	0.409	1.58	0.056	2.87	0.005	2.31	0.026
HMIP-2	rs9399137	T>C	0.145	4.57	0.00078	0.93	0.239	−0.607	0.797
	rs9402686	G>A	0.150	5.18	0.00005	1.00	0.185	−0.621	0.842

HbF, fetal hemoglobin; SNP, single nucleotide polymorphisms; MTD, maximum tolerated dose; MAF, Minor Allele Frequency; β is the beta coefficient that represents the average change in %HbF per allele copy of each individual SNP (effect size). The P-values were calculated using linear regression testing of each HbF phenotype. The presented P-values for the MTD HbF analysis include covariate correction for baseline HbF.